10-Q: Tharimmune Secures $545M, Pivots to Crypto Treasury Strategy

Tharimmune, a clinical-stage biotech, reported a reduced net loss in Q3 2025 and secured over $545 million in new capital, including a significant cryptocurrency offering, while also announcing major leadership changes and a new digital asset treasury strategy.

Summary

• Net loss for the three months ended September 30, 2025, decreased to $2.1 million from $3.8 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, decreased to $6.5 million from $8.4 million in the prior year period.
• Research and development expenses decreased by 88% to $0.3 million for the three months ended September 30, 2025, and by 67% to $1.4 million for the nine months ended September 30, 2025.
• General and administrative expenses increased by 15% to $1.8 million for the three months ended September 30, 2025, and by 19% to $5.1 million for the nine months ended September 30, 2025.
• Cash and cash equivalents increased to $7.6 million as of September 30, 2025, from $3.6 million at December 31, 2024.
• The company raised approximately $9.7 million in net proceeds from public and private equity offerings during the nine months ended September 30, 2025.
• Subsequent to the quarter, Tharimmune closed a cash offering for approximately $99.4 million and a cryptocurrency offering for approximately $446.2 million in Canton Coin.
• A new At-the-Market (ATM) agreement was established in November 2025, allowing for sales of up to $65 million in common stock.
• The company adopted a Canton-centric Digital Asset Treasury Strategy, intending to hold treasury assets in Canton Coin (CC) and participate in the Canton Network.
• FDA provided positive feedback on a Pre-Investigational New Drug Application (PIND) for TH104 for temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids (PrHPO), which is expected to be the lead program.
• The company's subsidiary, Hillstream Oncology, Inc., was renamed Gravitas Life Sciences, Inc.

Sentiment

Score: 6

Explanation: The significant capital raise and positive FDA feedback for TH104 are strong positives, addressing immediate liquidity concerns and offering a clearer path for a lead program. However, the substantial pivot to a digital asset treasury strategy, particularly with Canton Coin, introduces novel and high-magnitude risks (regulatory, market volatility, custody, 1940 Act classification) that are outside the company's core biotech expertise. This creates considerable uncertainty and could lead to significant volatility, balancing out the financial improvements and pipeline progress.

Positives

• Net loss significantly decreased for both the three-month ($2.1M vs $3.8M) and nine-month ($6.5M vs $8.4M) periods ended September 30, 2025, compared to the prior year.
• Research and development expenses saw substantial reductions, decreasing by 88% ($2.0M) for the three-month period and 67% ($2.9M) for the nine-month period, indicating improved cost management or a shift in development focus.
• Cash and cash equivalents more than doubled to $7.6 million by September 30, 2025, from $3.6 million at December 31, 2024, improving liquidity.
• The company successfully raised substantial capital post-period end, including $99.4 million in cash and $446.2 million in Canton Coin, significantly bolstering its financial position and addressing immediate going concern doubts.
• Positive FDA feedback for TH104's new indication (PrHPO) suggests a potentially faster regulatory pathway (505(b)(2) NDA) with no additional clinical trials required for prophylactic dosing, making it the new lead program.
• The establishment of a new $65 million ATM agreement provides additional flexible funding capacity.

Negatives

• General and administrative expenses increased by 15% ($0.2M) for the three-month period and 19% ($0.8M) for the nine-month period ended September 30, 2025, primarily due to personnel and non-cash stock compensation.
• Interest income decreased significantly by 98% ($71K) for the three-month period and 92% ($0.2M) for the nine-month period, reflecting lower cash balances in the prior year and decreased interest rates.
• The company continues to incur operating losses and had an accumulated deficit of $43.4 million as of September 30, 2025.
• The company explicitly stated substantial doubt about its ability to continue as a going concern for at least one year following the financial statement issuance date, although this is expected to be reevaluated due to recent financings.

Risks

• Regulatory developments related to crypto assets and crypto asset markets could adversely affect the business, financial condition, and results of operations.
• If Canton Coin is determined to constitute a security, the company could be classified as an investment company under the Investment Company Act of 1940, leading to significant additional regulatory controls and potentially forcing the sale of Canton Coins at unattractive prices.
• The Digital Asset Treasury (DAT) exposure to Canton Coin (CC) involves novel and significant risks including market volatility, accounting volatility (fair value changes recognized in earnings), regulatory uncertainty, custody risks (loss/destruction of private keys, cyberattacks, insolvency of third-party custodians), liquidity risks, and reputational risks.
• The lack of a permanent chief financial officer and internal accounting and finance staff could result in material weaknesses in internal controls over financial reporting.
• The company's financial results and the market price of its Common Stock may be significantly affected by the volatile prices of Canton Coin.
• Custody of Canton Coin tokens involves risks such as loss or destruction of private keys, cyberattacks, and potential treatment as a general unsecured creditor in custodian insolvency proceedings.
• Engaging in staking, restaking, or other permitted activities involving smart contracts or decentralized applications introduces risks from coding flaws, security vulnerabilities, or admin key misuse.
• The Canton Coin treasury reserve business model exposes the company to enhanced regulatory oversight, potential limitations on validator operations, increased litigation risks, and uncertainty around CC's regulatory status.
• The company may need substantial additional funding to support future operating activities, and there is no assurance it will obtain capital on acceptable terms or at all, which could delay or terminate clinical trial activities.

Future Outlook

The company expects TH104 for PrHPO to be its lead program, pursuing a capital-efficient strategy to file a 505(b)(2) New Drug Application (NDA) after completing additional nonclinical studies, with no further clinical trials anticipated for prophylactic dosing. The pruritus in PBC indication for TH104 will be pursued subsequently. The company intends to increase personnel headcount to support continued research and development activities. It will reevaluate its going concern assumption at year-end due to recent financing activities. The new digital asset treasury strategy is designed to supplement capital allocation and potentially offer strategic advantages for product development and global expansion over time, but its day-to-day operations remain focused on therapeutic candidates.

Management Comments

• We expect TH104 for PrHPO will be the lead program for the Company.
• We intend to conduct a capital efficient strategy to file an NDA for PrHPO.
• We have concluded that the prevailing conditions and ongoing liquidity risks faced by us raise substantial doubt about our ability to continue as a going concern for at least one year following the date these condensed consolidated financial statements are issued.
• Due to the recent financing activities, we will reevaluate the going concern assumption at year-end.
• Our Canton digital asset strategy was adopted by us as part of our broader strategy to enhance our platform with capital efficiency, to diversify treasury management practices, and engage with emerging financial technologies.
• Our adoption of a digital asset treasury strategy is not expected to materially alter our day-to-day operations, which remain focused on developing a portfolio of therapeutic candidates for inflammation and immunology.

Industry Context

Tharimmune operates in the highly competitive and capital-intensive biotechnology sector, focusing on immunology and inflammation. Its pipeline includes TH104, targeting chronic pruritus and opioid depression prophylaxis, and early-stage immuno-oncology candidates. The company's strategic pivot to integrate a significant digital asset treasury strategy, particularly with Canton Coin, is a highly unusual move for a clinical-stage biotech. This introduces a novel and speculative element, diverging from traditional biotech financing and treasury management, and positions the company at the intersection of biotech and emerging blockchain finance, a largely uncharted territory for public companies in this sector. This strategy could be seen as an attempt to leverage new financial technologies for capital efficiency and diversification, but it also exposes the company to the nascent and volatile crypto market, which is distinct from its core therapeutic development business.

Comparison to Industry Standards

• NA The filing does not provide specific comparisons to comparable companies, projects, or results within the biotechnology or digital asset industries.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that will have a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• The company's Chairman, Vincent LoPriore, is a partner and licensed broker at President Street Global, a consultant for the company, and his combined ownership is approximately 20.72% of outstanding common stock.
• The Chairman purchased 337,338 common shares and warrants in the June 2025 PIPE Offering for $500,000.
• Payments to President Street Global for services rendered, including offering commissions, totaled $0.6 million for the three months and $1.5 million for the nine months ended September 30, 2025.
• President Street Global received placement agent warrants to purchase up to 326,750 shares of common stock as compensation for various PIPE offerings.
• The CEO, Sireesh Appajosyula, individually and through affiliated companies, owns 4.02% of outstanding common stock (including vested options).
• The CEO purchased 60,806 common shares and warrants in the June 2025 PIPE Offering.
• In October 2025, the company agreed to pay an early lump-sum payment of approximately $0.9 million to President Street Global in lieu of remaining monthly installments of a consulting agreement.
• On October 1, 2025, the company entered into a new advisory agreement with President Street Global for a period of six months, with monthly payments of $150,000.
• In connection with the November 2025 offerings, the Board approved cash bonuses of $2.05 million for Chairman Vincent LoPriore, $1.9 million for Sireesh Appajosyula (CEO of Gravitas Life Sciences), and $2.05 million for other non-executive employees.

Stakeholder Impact

• **Shareholders**: Significant dilution from multiple equity offerings and warrants, but also a substantial capital infusion addressing liquidity concerns. The new digital asset treasury strategy introduces high volatility and regulatory risks, potentially impacting share price. Shareholder approval is required for the exercise of a large portion of the cryptocurrency warrants.
• **Employees**: Cash bonuses approved for employees, including substantial bonuses for the Chairman and former CEO, potentially boosting morale but also raising questions about executive compensation relative to company performance and risk profile. New employment agreements for the CEO and President offer competitive salaries and equity, aiming to attract and retain key talent.
• **Customers/Patients**: Continued development of therapeutic candidates like TH104 (for pruritus and opioid prophylaxis) and immuno-oncology programs could eventually lead to new treatment options.
• **Creditors**: Improved liquidity from recent capital raises reduces immediate credit risk, but the speculative nature of the digital asset treasury strategy could introduce new financial uncertainties.
• **Regulatory Authorities**: The company's digital asset treasury strategy, particularly holding Canton Coin, will likely attract increased scrutiny from the SEC and other financial regulators, especially regarding the classification of CC as a security and potential implications under the 1940 Act.

Next Steps

• Actively progress Chemistry, Manufacturing, and Controls (CMC) plan for TH104 buccal film formulation to meet FDA NDA requirements for PrHPO indication.
• Perform additional nonclinical studies (in vitro toxicology studies) for TH104's PrHPO indication.
• Submit a 505(b)(2) New Drug Application (NDA) for TH104 for PrHPO.
• Pursue the pruritus in PBC indication for TH104 subsequent to the PrHPO NDA filing.
• Reevaluate the going concern assumption at year-end due to recent financing activities.
• Seek additional funding through equity/debt, strategic partnerships, or grants if needed.
• Increase personnel headcount to support continued research activities and product candidate development.
• Obtain shareholder approval for the exercise of Cryptocurrency Pre-Funded Warrants into Common Stock.
• Apply to be a Super Validator and invest in the development of applications on the Canton Network to generate Canton Coin rewards.
• Monitor assets and income for compliance under the 1940 Act, potentially taking steps to reduce Canton Coin holdings if deemed investment securities.

Key Dates

Recommendation

While Tharimmune has significantly improved its liquidity through recent capital raises, including a substantial cryptocurrency offering, the company's strategic pivot to a Canton-centric Digital Asset Treasury Strategy introduces an entirely new and highly speculative risk profile that fundamentally deviates from its core biotechnology business. This strategy exposes the company to extreme market volatility, significant regulatory uncertainty (including potential classification as an investment company under the 1940 Act), and novel custody and cybersecurity risks associated with digital assets. These risks are substantial and largely unproven for a clinical-stage biotech. Furthermore, the company still faces an accumulated deficit, and while R&D expenses decreased, the long-term success of its early-stage therapeutic pipeline remains highly uncertain. The large bonuses tied to the capital raise for management, particularly the Chairman and former CEO, also raise corporate governance concerns. Given the high-risk, speculative nature of the new digital asset strategy, which overshadows any biotech pipeline progress, a seasoned investor would likely view this as a 'strong sell' due to the unpredictable and potentially catastrophic risks introduced.

Keywords

Biotechnology, Immunology, Inflammation, TH104, Pruritus, Primary Biliary Cholangitis, PrHPO, Opioid Prophylaxis, Oral Infliximab, INT-023/TH023, Immuno-oncology, HS1940, HS3215, Digital Asset Treasury, Canton Coin, Blockchain, SEC Filing, 10-Q, Clinical Stage, Capital Raise, Private Placement, ATM Offering, Going Concern